Case number 1:23-cv-00335
Bayer Intellectual Property GMBH et al v. ScieGen Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 3, 2023 | N/A | CORRECTING ENTRY: The stipulation (D.I. 11) and Order (D.I. 12) filed on 5/3/2023, have been removed from the docket. It was realized after entry of the Order that the captions of the filings lacked reference to the MDL this case is a member of. The case has subsequently been reopened. Counsel is to refile an amended stipulation in both this case and the MDL (21md3017-RGA). (nms) (Entered: 05/03/2023) (0) |
| May 3, 2023 | 11 | STIPULATION of Dismissal, by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 5/3/2023 (nms). (Entered: 05/03/2023) (2) |
| May 3, 2023 | 12 | SO ORDERED Granting (D.I. 151 in 21-md-3017-RGA; D.I. 11 in 23-cv-335-RGA) Stipulation of Dismissal. Signed by Judge Richard G. Andrews on 5/3/2023. Associated Cases: 1:23-cv-00335-RGA, 1:21-md-03017-RGA(nms) (Entered: 05/03/2023) (2) |
| May 3, 2023 | N/A | CASE CLOSED per entry of D.I. 12 (nms) (Entered: 05/03/2023) (0) |
| May 3, 2023 | 13 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2; 10,828,310 B2. (Attachments: # 1 Order)(nms) (Entered: 05/03/2023) (Main Document) (1) |
| May 3, 2023 | 13 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2; 10,828,310 B2. (Attachments: # 1 Order)(nms) (Entered: 05/03/2023) (Order) (2) |
| Apr 13, 2023 | N/A | DEFICIENCY NOTICE issued by the Court to Defendant: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by ScieGen Pharmaceuticals, Inc.. (Rogowski, Patricia) (Entered: 04/13/2023) (1) |
| Apr 12, 2023 | 8 | WAIVER OF SERVICE returned executed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, Bayer Pharma AG: For ScieGen Pharmaceuticals, Inc. waiver sent on 3/28/2023, answer due 5/30/2023. (Fahnestock, Derek) (Entered: 04/12/2023) (1) |
| Apr 12, 2023 | 9 | NOTICE of Appearance by Patricia Smink Rogowski on behalf of ScieGen Pharmaceuticals, Inc. (Rogowski, Patricia) (Entered: 04/12/2023) (1) |
| Mar 29, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:23-cv-00327-UNA, 1:23-cv-00334-UNA, 1:23-cv-00335-UNA(nms) (Entered: 03/29/2023) (0) |
| Mar 27, 2023 | N/A | Remark: The MDL Panel has been notified of case opening. (mpb) (Entered: 03/27/2023) (0) |
| Mar 24, 2023 | 1 | COMPLAINT filed against ScieGen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4097351.) - filed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, Bayer Pharma AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(mpb) (Entered: 03/27/2023) (Main Document) (17) |
| Mar 24, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 03/27/2023) (3) |
| Mar 24, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/18/2023. Date of Expiration of Patent: 2/17/2024 for U.S. Patent 9,539,218 and 1/31/2039 for U.S. Patent 10,828,310.Thirty Month Stay Deadline: 8/18/2025. (mpb) (Entered: 03/27/2023) (1) |
| Mar 24, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2; 10,828,310 B2. (mpb) (Entered: 03/27/2023) (1) |
| Mar 24, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Intellectual Property GMBH, Bayer Pharma AG filed by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG. (mpb) (Entered: 03/27/2023) (1) |
| Mar 24, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc.. (mpb) (Entered: 03/27/2023) (1) |
| Mar 24, 2023 | 7 | Summons Issued as to ScieGen Pharmaceuticals, Inc. on 3/24/2023. (mpb) (Entered: 03/27/2023) (2) |
| Mar 24, 2023 | 1 | COMPLAINT filed against ScieGen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4097351.) - filed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, Bayer Pharma AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(mpb) (Entered: 03/27/2023) (Exhibit A) (14) |
| Mar 24, 2023 | 1 | COMPLAINT filed against ScieGen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4097351.) - filed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, Bayer Pharma AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(mpb) (Entered: 03/27/2023) (Exhibit B) (27) |
| Mar 24, 2023 | 1 | COMPLAINT filed against ScieGen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4097351.) - filed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, Bayer Pharma AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(mpb) (Entered: 03/27/2023) (Civil Cover Sheet) (2) |
